Also known as Tesamorelin/Ipamorelin · Tesa Ipa
A GH-secretagogue pairing built on an FDA-approved GHRH analog (Tesamorelin) plus a selective secretagogue (Ipamorelin).
Research refreshed
A combination of Tesamorelin — a stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy — with Ipamorelin, a selective ghrelin-receptor secretagogue. It applies the same two-receptor logic as the CJC-1295 + Ipamorelin pairing, but uses a GHRH analog that has cleared clinical trials and carries an approved indication. The blend itself is a research combination: Tesamorelin is approved as a single agent, not in combination with Ipamorelin, and the mixture has no dedicated trial.
This pairing is the “clinical-grade GHRH” version of the GHRH-plus-secretagogue stack. Tesamorelin is a GHRH analog with real trial data and an FDA approval for reducing visceral fat in HIV lipodystrophy; Ipamorelin adds a selective ghrelin-receptor signal on top. The two receptors are distinct, which is the basis for combining them.
The approval belongs to Tesamorelin alone. There is no trial of the Tesamorelin + Ipamorelin combination, so the blend inherits Tesamorelin’s evidence only for Tesamorelin, and Ipamorelin remains an unapproved research peptide. This page is a research reference, not a protocol.
Tesamorelin: GHRH-receptor agonism (stabilized against DPP-4) driving GH synthesis and release, with documented visceral-fat reduction. Ipamorelin: selective GHS-R1a agonism amplifying the GH pulse. Dual-pathway stimulation is studied for a larger pulse than either alone.
Behind every vial of Tesamorelin + Ipamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Tesamorelin + Ipamorelin, specifically, is brought into being.
Tesamorelin + Ipamorelin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Tesamorelin + Ipamorelin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Tesamorelin + Ipamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Tesamorelin + Ipamorelin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Tesamorelin + Ipamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A physical mixture of two separately made peptides — Tesamorelin (a stabilized 44-residue GHRH analog) and Ipamorelin (a short pentapeptide secretagogue). Tesamorelin is the harder, longer synthesis of the two; the blend has no combined purity number, so a real certificate assays each peptide on its own and states the amount of each. Pooling a long and a short peptide in one solution also raises stability questions a single-peptide vial does not.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
A pairing of an FDA-approved GHRH analog (Tesamorelin) with a selective GH secretagogue (Ipamorelin), combining two receptor pathways to raise growth hormone.
No. Tesamorelin alone is approved for HIV-associated lipodystrophy; the combination with Ipamorelin has not been studied or approved as a blend.
Same two-receptor logic, but the GHRH component here (Tesamorelin) is a clinically approved, trial-backed analog rather than a research GHRH peptide.
No — only Tesamorelin as a single agent. This page is a research and educational reference.
Tesamorelin + Ipamorelin is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.